New and Future Drug Development for Gastroesophageal Reflux Disease
´ëÇѼÒÈ°ü¿îµ¿ÇÐȸÁö 2014³â 20±Ç 1È£ p.6 ~ p.16
(Maradey-Romero Carla) - Case Western Reserve University MetroHealth Medical Center Division of Gastroenterology and Hepatology
(Fass Ronnie) - Case Western Reserve University MetroHealth Medical Center Division of Gastroenterology and Hepatology
Abstract
Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug devel-opment for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)¡¯s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist¡¯s, extended release PPI¡¯s, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies.
Å°¿öµå
Erosive esophagitis, Gastroesophageal reflux, Heartburn, Proton pump inhibitors
KMID :
0812020140200010006
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)